B7-H4 Targeted Antibody Therapy Pipeline Review

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: tbd
Format: PDF & Online Database
Product Line: Target Pipeline Review
Product Code: LMTP0146
Release Date: August of 2024
Loading...

B7-H4 Targeted Antibody Therapy Pipeline Review

Target 1: B7-H4

Product Category: Antibody

This product provides basic pipeline information on investigational antibodies targeting B7-H4.

This product consists of:

  • Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
  • Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
  • One-month online access to La Merie Publishing’s database for investigational antibody therapies targeting B7-H4 (prerequisite: access to internet).

This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.

B7-H4 is a member of the B7 family of immune checkpoint ligands and has been shown to negatively regulate T-cell function. B7-H4 binds to an unknown receptor on T cells and inhibits T-cell proliferation and cytokine production. B7-H4 expression is elevated across a broad range of solid tumors, including ovarian cancer, breast cancer, endometrial carcinoma, cholangiocarcinoma and gallbladder carcinoma, and squamous non-small cell lung cancer tumors. B7-H4 expression is limited in normal tissue, specifically immune cells, making it an ideal molecular target.

A number or antibody modality technologies were used to generate anti-B7-H4 drug candidates undergoing preclinical and clinical development, including antibody-drug conjugates, conditionally activated antibodies, T-cell engaging bispecific antibodies and other effector-enhanced antibody molecules.

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.

Contacts

Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01

Error: Contact form not found.